What were the key financial metrics reported for Q2 2025, and how do they compare to analysts' expectations? | ZEAL (Aug 07, 2025) | Candlesense
ZEAL

What were the key financial metrics reported for Q2 2025, and how do they compare to analysts' expectations?

I’m sorry, but the excerpt you provided does not contain the actual financial figures or the analysts’ expectations that were disclosed in Zealand Pharma’s Q2 2025 earnings release. The information available (the title, summary line, and metadata) tells us only that a conference call was scheduled for August 14 2025 to present the second‑quarter results, but it does not include:

  • Revenue for the quarter (or year‑to‑date)
  • Net income or loss
  • Earnings‑per‑share (EPS) figures
  • Gross margin, operating margin, cash‑flow numbers, or any other key performance indicators
  • The consensus forecasts or target numbers that analysts had published beforehand

Because those metrics are not present in the text you shared, I’m unable to provide a comparison between the reported results and analysts’ expectations.

If you can supply the specific figures from the press release (or a more detailed excerpt of the earnings announcement), I’ll be able to:

  1. List the key financial metrics (e.g., revenue, GAAP and non‑GAAP EPS, net income, cash from operations, R&D spend, etc.).
  2. Show the consensus estimates that analysts had compiled (usually from sources like FactSet, Bloomberg, or Refinitiv).
  3. Highlight where Zealand Pharma’s results beat, missed, or matched those expectations and note any commentary the company gave about the variance.

Feel free to paste the relevant portions of the earnings release, and I’ll gladly provide the comprehensive comparison you’re looking for.

Other Questions About This News

What are the implications of the earnings results for the company's long‑term growth and valuation? What is the market's reaction to the earnings release so far, and how is the stock price moving post‑release? How does the company's financial performance compare to that of its main competitors in the biotech/pharmaceutical sector? What were the earnings per share (EPS) figures, and how do they stack up against consensus estimates? Did management address any macro‑economic or regulatory factors that could affect future performance? Are there any updates on the company's pipeline, especially concerning any late-stage clinical trials or FDA submissions? How does the reported revenue and profitability trend compare to the same quarter last year? Did Zealand Pharma provide any guidance or outlook for the upcoming quarters or fiscal year? Did the company announce any significant partnerships, acquisitions, or divestitures during the call?